NYSEAMERICAN:ELMD

Electromed Competitors

$10.05
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.00
Now: $10.05
$10.30
50-Day Range
$9.48
MA: $9.91
$10.28
52-Week Range
$8.10
Now: $10.05
$19.73
Volume37,787 shs
Average Volume62,203 shs
Market Capitalization$86.78 million
P/E Ratio23.93
Dividend YieldN/A
Beta0.42

Competitors

Electromed (NYSEAMERICAN:ELMD) Vs. EDAP, EYES, BSGM, FONR, IRIX, and NDRA

Should you be buying ELMD stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Electromed, including Edap Tms (EDAP), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), FONAR (FONR), IRIDEX (IRIX), and ENDRA Life Sciences (NDRA).

Edap Tms (NASDAQ:EDAP) and Electromed (NYSEAMERICAN:ELMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Volatility and Risk

Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Insider and Institutional Ownership

37.5% of Electromed shares are owned by institutional investors. 19.6% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Edap Tms and Electromed's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$50.23 million5.11$1.69 million$0.06146.83
Electromed$32.47 million2.67$4.16 million$0.4721.38

Electromed has lower revenue, but higher earnings than Edap Tms. Electromed is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edap Tms and Electromed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edap Tms-4.03%-11.54%-5.78%
Electromed11.44%12.39%11.15%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Edap Tms and Electromed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edap Tms00303.00
Electromed00203.00

Edap Tms currently has a consensus price target of $12.50, indicating a potential upside of 41.88%. Electromed has a consensus price target of $18.00, indicating a potential upside of 79.10%. Given Electromed's higher possible upside, analysts clearly believe Electromed is more favorable than Edap Tms.

Summary

Electromed beats Edap Tms on 9 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and Electromed (NYSEAMERICAN:ELMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Earnings and Valuation

This table compares Second Sight Medical Products and Electromed's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million59.50$-33,590,000.00($1.91)-4.53
Electromed$32.47 million2.67$4.16 million$0.4721.38

Electromed has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 37.5% of Electromed shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by insiders. Comparatively, 19.6% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Second Sight Medical Products and Electromed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
Electromed11.44%12.39%11.15%

Volatility and Risk

Second Sight Medical Products has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Second Sight Medical Products and Electromed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
Electromed00203.00

Electromed has a consensus price target of $18.00, suggesting a potential upside of 79.10%. Given Electromed's higher probable upside, analysts plainly believe Electromed is more favorable than Second Sight Medical Products.

Summary

Electromed beats Second Sight Medical Products on 10 of the 13 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Electromed (NYSEAMERICAN:ELMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership and profitability.

Insider & Institutional Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 37.5% of Electromed shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 19.6% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for BioSig Technologies and Electromed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
Electromed00203.00

Electromed has a consensus target price of $18.00, indicating a potential upside of 79.10%. Given Electromed's higher probable upside, analysts clearly believe Electromed is more favorable than BioSig Technologies.

Profitability

This table compares BioSig Technologies and Electromed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
Electromed11.44%12.39%11.15%

Valuation & Earnings

This table compares BioSig Technologies and Electromed's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
Electromed$32.47 million2.67$4.16 million$0.4721.38

Electromed has higher revenue and earnings than BioSig Technologies.

Volatility & Risk

BioSig Technologies has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Summary

Electromed beats BioSig Technologies on 9 of the 10 factors compared between the two stocks.

FONAR (NASDAQ:FONR) and Electromed (NYSEAMERICAN:ELMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Institutional and Insider Ownership

62.1% of FONAR shares are owned by institutional investors. Comparatively, 37.5% of Electromed shares are owned by institutional investors. 8.6% of FONAR shares are owned by company insiders. Comparatively, 19.6% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

FONAR has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for FONAR and Electromed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FONAR0000N/A
Electromed00203.00

Electromed has a consensus price target of $18.00, indicating a potential upside of 79.10%. Given Electromed's higher possible upside, analysts clearly believe Electromed is more favorable than FONAR.

Profitability

This table compares FONAR and Electromed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FONAR8.28%5.57%3.99%
Electromed11.44%12.39%11.15%

Earnings and Valuation

This table compares FONAR and Electromed's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FONAR$85.69 million1.38$8.24 millionN/AN/A
Electromed$32.47 million2.67$4.16 million$0.4721.38

FONAR has higher revenue and earnings than Electromed.

Summary

Electromed beats FONAR on 8 of the 12 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and Electromed (NYSEAMERICAN:ELMD) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for IRIDEX and Electromed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IRIDEX00203.00
Electromed00203.00

IRIDEX presently has a consensus price target of $6.50, suggesting a potential downside of 9.97%. Electromed has a consensus price target of $18.00, suggesting a potential upside of 79.10%. Given Electromed's higher possible upside, analysts plainly believe Electromed is more favorable than IRIDEX.

Institutional & Insider Ownership

32.6% of IRIDEX shares are held by institutional investors. Comparatively, 37.5% of Electromed shares are held by institutional investors. 2.0% of IRIDEX shares are held by insiders. Comparatively, 19.6% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Profitability

This table compares IRIDEX and Electromed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IRIDEX-21.54%-38.60%-24.99%
Electromed11.44%12.39%11.15%

Earnings and Valuation

This table compares IRIDEX and Electromed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$43.45 million2.58$-8,810,000.00($0.64)-11.28
Electromed$32.47 million2.67$4.16 million$0.4721.38

Electromed has lower revenue, but higher earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Summary

Electromed beats IRIDEX on 10 of the 12 factors compared between the two stocks.

ENDRA Life Sciences (NASDAQ:NDRA) and Electromed (NYSEAMERICAN:ELMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Institutional & Insider Ownership

2.8% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 37.5% of Electromed shares are owned by institutional investors. 9.6% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 19.6% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

ENDRA Life Sciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Valuation and Earnings

This table compares ENDRA Life Sciences and Electromed's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life Sciences$10,000.009,776.00$-13,310,000.00($2.34)-1.00
Electromed$32.47 million2.67$4.16 million$0.4721.38

Electromed has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ENDRA Life Sciences and Electromed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ENDRA Life SciencesN/A-492.76%-288.58%
Electromed11.44%12.39%11.15%

Analyst Ratings

This is a breakdown of recent ratings for ENDRA Life Sciences and Electromed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ENDRA Life Sciences0000N/A
Electromed00203.00

Electromed has a consensus price target of $18.00, indicating a potential upside of 79.10%. Given Electromed's higher probable upside, analysts plainly believe Electromed is more favorable than ENDRA Life Sciences.

Summary

Electromed beats ENDRA Life Sciences on 11 of the 13 factors compared between the two stocks.


Electromed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$8.81flat$256.74 million$50.23 million-146.83
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.65flat$201.11 million$3.38 million-4.53
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.35flat$138.29 millionN/A0.00
FONR
FONAR
1.1$18.01flat$118.04 million$85.69 million16.99
IRIDEX logo
IRIX
IRIDEX
0.9$7.22flat$112.06 million$43.45 million-13.13
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.35flat$97.76 million$10,000.00-1.28
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.12flat$89.29 millionN/A-1.47
electroCore logo
ECOR
electroCore
1.4$1.83flat$88.71 million$2.39 million-2.32
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.28flat$39.93 million$1.50 million-0.99
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10flat$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.35flat$32.30 million$5.51 million-0.11
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.12flat$32.27 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.50flat$25.59 million$15.09 million0.00Gap Down
PEYE
Precision Optics
0.4$1.62flat$22.35 million$9.92 million-16.20Gap Up
Vaso logo
VASO
Vaso
0.9$0.12flat$21.30 million$75.75 million5.93News Coverage
Gap Up
STRR
Star Equity
0.1$3.24flat$15.95 million$114.18 million-1.03
Micron Solutions logo
MICR
Micron Solutions
0.1$3.48flat$11.70 million$17.50 million24.86
GTHP
Guided Therapeutics
0.3$0.81flat$10.41 million$40,000.00-3.35High Trading Volume
Gap Down
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.69 millionN/A0.00
RSLSD
ReShape Lifesciences
0.5$5.37flat$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.02flat$1.20 millionN/A5.67
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$447,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$356,000.00N/A0.00
ULGX
Urologix
0.6$0.01flat$192,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00flat$177,000.00N/A0.00
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.34flat$0.00$9.40 million-5.67Gap Up
HRTT
Heart Tronics
0.0$0.15flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
PECN
Photoelectron
0.2$0.03flat$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.